Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

eqs_en 
0 0 23.10.19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
 

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

23-Oct-2019 / 13:55 CET/CEST
Update of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

 
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

Jena, October 23, 2019

As already announced on October 2, 2019, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,459 million in fiscal year 2018/19 (past year: EUR 1,280.9 million) and has significantly expanded EBIT[1] margin[2], exceeding the initial forecast of 15.0% to 17.5%. Based on today's new assessment, EBIT for fiscal year 2018/19 amounted to approx. EUR 264 million (past year: EUR 197.1 million), leading to an EBIT margin of 18.1%.

Upon publication of preliminary results on October 2, 2019, the company had anticipated a still higher EBIT margin for fiscal year 2018/19.

The shortfall was caused by higher operating expenses in the fourth quarter of fiscal year 2018/19, in part driven by the already announced higher investments in the fields of Surgical Ophthalmology and Digitalization.

Final results for fiscal year 2018/19 will be provided on December 6, 2019.
 
 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]

[1] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation).
[2] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).

23-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 894865

 
End of Announcement DGAP News Service

894865  23-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=894865&application_name=news&site_id=sharewise

Carl Zeiss Meditec AG Stock

€99.25
-1.150%
We can see a decrease in the price for Carl Zeiss Meditec AG. Compared to yesterday it has lost -€1.150 (-1.150%).
With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Carl Zeiss Meditec AG.
With a target price of 101 € there is a slightly positive potential of 1.76% for Carl Zeiss Meditec AG compared to the current price of 99.25 €.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!